# C_2009087EN.01001301.xml

| 16.4.2009 | EN | Official Journal of the European Union | C 87/13 |
| --- | --- | --- | --- |

16.4.2009

EN

Official Journal of the European Union

C 87/13

---

Prior notification of a concentration

(Case COMP/M.5479 — LONZA/TEVA/JV)

(Text with EEA relevance)

2009/C 87/05

| 1. | On 3 April 2009 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Lonza Group Ltd (‘Lonza’) and Teva Pharmaceuticals Industries Ltd (‘Teva’) (Lonza and Teva together, ‘the Parent Companies’) create a Joint Venture (‘the JV’), within the meaning of Article 3(4) of the Council Regulation. |
| --- | --- |

1.

On 3 April 2009 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Lonza Group Ltd (‘Lonza’) and Teva Pharmaceuticals Industries Ltd (‘Teva’) (Lonza and Teva together, ‘the Parent Companies’) create a Joint Venture (‘the JV’), within the meaning of Article 3(4) of the Council Regulation.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Lonza: the supply of various services from research to final product manufacture in the pharmaceutical, health care and life science industries, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Lonza: the supply of various services from research to final product manufacture in the pharmaceutical, health care and life science industries,

| — | for Teva: the development, production and marketing of generic pharmaceutical products and proprietary pharmaceutical products as well as (chemical) active pharmaceutical ingredients, |
| --- | --- |

—

for Teva: the development, production and marketing of generic pharmaceutical products and proprietary pharmaceutical products as well as (chemical) active pharmaceutical ingredients,

| — | for the JV: the development, production and commercialisation of biosimilar products worldwide. |
| --- | --- |

—

for the JV: the development, production and commercialisation of biosimilar products worldwide.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5479 — LONZA/TEVA/JV, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5479 — LONZA/TEVA/JV, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---